Lung Cancer Treatment Insurance Denied? How to Appeal

Lung cancer treatment has transformed dramatically over the past decade. Immunotherapy, targeted therapies, and comprehensive molecular testing have improved survival rates significantly — but they have also created new categories of insurance denial. If your insurer has rejected a lung cancer treatment your oncologist recommends, you have strong legal and clinical grounds for appeal. Lung cancer is classified under ICD-10 codes C34.10–C34.92 (malignant neoplasm of bronchus and lung), and treatments denied under these codes are among the most successfully appealed oncology claims when the right documentation is presented.

Why Insurers Deny Lung Cancer Treatment

Insurance companies deny lung cancer treatment claims for several predictable reasons. Biomarker testing — including next-generation sequencing (NGS) panels and specific gene mutation tests for EGFR, ALK, ROS1, KRAS G12C, MET, RET, and NTRK alterations — is denied when insurers characterize comprehensive genomic profiling as investigational. Targeted therapies such as osimertinib (Tagrisso), alectinib (Alecensa), lorlatinib (Lorbrena), and sotorasib (Lumakras) are denied due to formulary restrictions, Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization failures, or off-label use arguments. Immunotherapy agents including pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq) are denied when PD-L1 expression thresholds in the coverage policy differ from the biomarker results in the clinical file.

Maintenance therapy and combination regimens are also frequently denied. Insurers apply step therapy requirements that demand less effective prior-line treatments even when the oncologist has determined the patient requires a specific regimen based on tumor histology and mutation profile.

How to Appeal a Lung Cancer Treatment Denial

Step 1: Request Your Complete Denial Letter and Clinical Criteria

Obtain the full denial letter and EOB)" class="auto-link">Explanation of Benefits (EOB) immediately. The denial must state the specific reason and the clinical criteria your insurer applied. Also request the complete adverse benefit determination file — under ERISA, you are entitled to all documents, records, and other information relevant to your claim, free of charge, within 30 days.

Step 2: Obtain Your Oncologist's Letter of Medical Necessity

Ask your oncologist to write a detailed letter of medical necessity addressing the insurer's specific denial reason. For targeted therapy denials, the letter should document the molecular alteration detected, the specific FDA-approved indication for the denied drug, and why alternative treatments are inadequate given the patient's tumor profile. For NGS panel denials, the letter should explain why comprehensive biomarker profiling is necessary to guide treatment selection.

Step 3: Cite NCCN Guidelines Directly

The National Comprehensive Cancer Network (NCCN) publishes lung cancer treatment guidelines that are widely recognized by insurers, regulators, and courts as the gold standard of oncology practice. NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (Category 1 and 2A recommendations) and NCCN Small Cell Lung Cancer Guidelines support specific first-line, second-line, and maintenance regimens. Reference the specific NCCN guideline category and version in your appeal letter. Most states require insurers to cover treatments recommended in NCCN compendium Category 1 or 2A.

Step 4: Address FDA Approval and Off-Label Use Statutes

If your treatment involves an off-label use, document that NCCN lists it as a recognized treatment for your specific cancer type and stage. Most states have laws requiring commercial insurers to cover off-label chemotherapy and targeted therapy supported by recognized compendia including NCCN, Micromedex, and Clinical Pharmacology. Request that your state insurance commissioner's office confirm which compendia your state requires insurers to honor.

Step 5: Request an Expedited Appeal Given Clinical Urgency

For active cancer treatment, request an expedited internal appeal. Under ACA regulations, urgent appeals must be decided within 72 hours. Ask your oncologist to certify in writing that the standard review timeline creates a risk to your health, which is a qualifying basis for expedited review.

Step 6: Escalate to External Independent Review: Complete Guide" class="auto-link">External Review and State Regulators

If your internal appeal is denied, immediately request an independent external review through your state insurance department. File a concurrent complaint with your state insurance commissioner, as regulators take oncology denials seriously and can accelerate resolution. External review is free, and many oncology denials are overturned when reviewed by an independent oncology specialist.

What to Include in Your Appeal

• Denial letter and EOB with the specific reason code and clinical criteria cited
• Your oncologist's letter of medical necessity citing tumor molecular profile and FDA approvals
• NCCN guideline citations for your specific cancer type, stage, and treatment (with guideline version)
• Molecular testing results showing the specific gene alteration that supports the targeted therapy
• FDA-approved labeling for the denied drug documenting the approved indication
• Documentation of prior treatments tried and failed if step therapy was cited as a denial reason

Fight Back With ClaimBack

A lung cancer treatment denial is one of the most urgent insurance appeals you can face. NCCN guidelines and FDA approvals provide powerful clinical ammunition — but the appeal must cite them correctly and be filed quickly. ClaimBack generates a professional appeal letter in 3 minutes, referencing NCCN guidelines, FDA approvals, and your oncologist's clinical documentation.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal